Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin（PLD）Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03994107
• Other study ID #: CSPC-DMS-BC-17
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2019
• Est. completion date: January 1, 2021

Study information

• Verified date: January 2020
• Source: Peking Union Medical College
• Contact: Fei Ma, MD
• Phone: +8613910217780
• Email: 13910217780[@]139.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal doxorubicin（PLD）plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2 positive breast cancer.

Description:

This is a single-center, prospective, single arm phase II study. Eligible patients will receive neoadjuvant therapy with pegylated liposome doxorubicin (PLD)/albumin-bound paclitaxel/trastuzumab regimentation.

This study consists of two phases, the first phase aims to determine the maximum tolerated dose (MTD) of PLD, and the second phase will explore the efficacy and safety of the regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 1, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Ability to understand and voluntarily receive the research procedures according to protocol,willingness to sign the written informed consent document;

2. Female patients aged from 18 to 70 years old;

3. Histologically confirmed as invasive breast cancer. occult breast cancer, inflammatory breast cancer and eczematoid carcinoma are ineligible;

4. Clinical stage?-?;

5. HER-2 Positive(defined by: IHC 3+ or ISH positive);

6. Without previous treatment for this breast cancer;

7. Patients must have at least one measurable disease according to RECIST 1.1;

8. ECOG (Eastern Cooperative Oncology Group) performance score of 0-1 points;

9. LVEF=55%;

10. Normal ECG;

11. Bone marrow function:absolute neutrophil count (ANC)=2.0×109/L,platelets=100×109/L,hemoglobin =90g/L?

12. Hepatic function:alanine aminotransferase(ALT) and aspartate aminotransferase(AST) =1.5×ULN,serum total bilirubin= ULN;

13. Renal function:serum creatinine=1.5×ULN; Coagulation function:the international standardized ratio (INR) =1.5×ULN, prothrombin time (PT) or the activated partial thrombin time (APTT) =1.5×ULN.

Exclusion Criteria:

1. New York Heart Association (NYHA) class =? heart failure.

2. Known or suspected hypersusceptibility to any agents used in the treatment protocol.

3. Need to Concurrent treatment with any other anti-cancer therapy considered by the investigator.

4. participating in other clinical trials within 4 weeks before this study.

5. Serious heart disease, including but not limited to:

1) Significant ventricular arrhythmia or high degree atrioventricular block (Mobitz II or third degree atrioventricular block); 2) unstable angina; 3) clinically significant heart valve disease; 4) Electrocardiogram shows transmural myocardial infarction; 5) Uncontrolled hypertension. 6. Uncontrolled diabetes. 7. Severe or uncontrolled infection. 8. Hepatitis b surface antigen positive, or hepatitis c virus antibody positive, or human immunodeficiency virus (HIV) antibody positive.

9. Active malignancy, other than adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin,within the past 5 years.

9)Women who are pregnant , breastfeeding ,or refuse to use adequate contraception prior to study entry and for the duration of study participation.

10)Other conditions considered to be inappropriate to be enrolled by the investigator.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Pegylated Liposomal Doxorubicin
First phase PLD: 30mg/m2;35mg/m2;40mg/m2;IV, d1, q21d×6. Second phase PLD:MTD. IV, d1, q21d×6.
• Albumin-bound paclitaxel
220mg/m2 IV for the first infusion,Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
• Trastuzumab
8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.

Locations

Country	Name	City	State
China	Fei Ma	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking Union Medical College	CSPC Ouyi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response(pCR) rate	Percentage of patients who do not exhibit residual invasive breast cancer in breast and lymph nodes at time of surgery	5 months
Secondary	Rate of Breast conserving surgery	Percentage of patients undergoing breast-conserving surgery after neoadjuvant therapy	5 months
Secondary	Rate of surgery	Percentage of patients undergoing mastectomy and breast-conserving surgery after neoadjuvant therapy	5 months
Secondary	adverse events	Incidence and Severity of adverse events ,according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0	5 months